Brian Elmengaard

Dr. Brian Elmengaard

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2012 in Acta Orthopaedica
Verified
Journal Article
Open access
HDHenrik Daugaard
Henrik Daugaard
BEBrian Elmengaard
Brian Elmengaard
TATroels Torp Andreassen
Troels Torp Andreassen
ALAnders Lamberg
Anders Lamberg
JBJoan Elisabeth Bechtold
Joan Elisabeth Bechtold
KSKjeld Soballe
Kjeld Soballe
Intermittent administration of parathyroid hormone (PTH) has an anabolic effect on bone, as confirmed in human osteoporosis studies, distraction osteogenesis, and fracture healing. PTH in rat models leads to improved fixation of implants in low-density bone or screw insertion transcortically. We examined the effect of human PTH (1-34) on the cancellous osseointegration of unloaded implants inserted press-fit in intact bone of higher animal species. 20 dogs were randomized to treatment with human PTH (1-34), 5 μg/kg/day subcutaneously, or placebo for 4 weeks starting on the day after insertion of a cylindrical porous coated plasma-sprayed titanium alloy implant in the proximal metaphyseal cancellous bone of tibia. Osseointegration was evaluated by histomorphometry and fixation by push-out test to failure. Surface fraction of woven bone at the implant interface was statistically significantly higher in the PTH group by 1.4 fold with (median (interquartile range) 15% (13-18)) in the PTH group and 11% (7-13) in control. The fraction of lamellar bone was unaltered. No significant difference in bone or fibrous tissue was observed in the circumferential regions of 0-500, 500-1,000, and 1,000-2,000 μm around the implant. Mechanically, the implants treated with PTH showed no significant differences in total energy absorption, maximum shear stiffness, or maximum shear strength. Intermittent treatment with PTH (1-34) improved histological osseointegration of a prosthesis inserted press-fit at surgery in cancellous bone, with no additional improvement of the initial mechanical fixation at this time point.

1 January 2011 in The Journal of Bone and Joint Surgery. British volume
Verified
Journal Article
Open access
HDH. Daugaard
H. Daugaard
BEBrian Elmengaard
Brian Elmengaard
TAT. T. Andreassen
T. T. Andreassen
JBJ. Baas
J. Baas
JBJ. E. Bechtold
J. E. Bechtold
KSKjeld Soballe
Kjeld Soballe
Impaction allograft is an established method of securing initial stability of an implant in arthroplasty. Subsequent bone integration can be prolonged, and the volume of allograft may not be maintained. Intermittent administration of parathyroid hormone has an anabolic effect on bone and may therefore improve integration of an implant. Using a canine implant model we tested the hypothesis that administration of parathyroid hormone may improve osseointegration of implants surrounded by bone graft. In 20 dogs a cylindrical porous-coated titanium alloy implant was inserted into normal cancellous bone in the proximal humerus and surrounded by a circumferential gap of 2.5 mm. Morsellised allograft was impacted around the implant. Half of the animals were given daily injections of human parathyroid hormone (1–34) 5 μg/kg for four weeks and half received control injections. The two groups were compared by mechanical testing and histomorphometry. We observed a significant increase in new bone formation within the bone graft in the parathyroid hormone group. There were no significant differences in the volume of allograft, bone-implant contact or in the mechanical parameters. These findings suggest that parathyroid hormone improves new bone formation in impacted morsellised allograft around an implant and retains the graft volume without significant resorption. Fixation of the implant was neither improved nor compromised at the final follow-up of four weeks.

18 February 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
RARasmus Aabling
Rasmus Aabling
MRMaria Rusan
Maria Rusan
AMAnaïs M. J. Møller
Anaïs M. J. Møller
NMNaija Munk-Pedersen
Naija Munk-Pedersen
CHCarsten Femhøj Holm
Carsten Femhøj Holm
BMBjarne Kuno Møller
Bjarne Kuno Møller
Knee osteoarthritis (OA) is a chronic, progressive, inflammatory, and degenerative whole-joint disease. Early-stage OA treatments typically include physiotherapy, weight-loss, pain relief medications, and intra-articular knee injections, such as corticosteroids, hyaluronic acid, or platelet-rich plasma. These treatments primarily provide symptomatic relief rather than reversing or halting disease progression. Recently, mesenchymal stromal cell (MSC) injections have garnered attention due to their immunomodulatory and regenerative capacities. MSCs, which can be derived from sources such as bone marrow, umbilical cord, or adipose tissue, and can be allogeneic or autologous, have demonstrated promising results in both animal models and several human studies. However, different protocols have been employed, presenting challenges for comparing outcomes. In this review, we address these variable settings, evaluate current practices, and identify key factors critical in optimizing MSC-based therapies by critically reviewing clinical trials of ex vivo expanded MSC therapies for OA undertaken between 2008 and 2023. Specific attention was given to two key aspects: (1) the cell culture process employed in manufacturing of autologous or allogeneic MSC products, and (2) the post-culture methods employed in storage, reconstitution and administration of the MSCs. Our findings suggest that standardizing MSC production for clinical applications remains a significant challenge, primarily due to variations in tissue sources, harvesting techniques, and manufacturing protocols, and due to broad discrepancies in reporting. Thus, we propose a set of minimal reporting criteria to guide future clinical trials. A common reporting guideline is a critical step towards a more standardized MSC production across different laboratories and clinical settings, thereby enhancing reproducibility and advancing the field of regenerative medicine for knee OA, as well as other disease settings.

8 August 2026 in Sociology of Health & Illness
Verified
Journal Article
Open access
PDF file
ASAnna Louise Skovgaard
Anna Louise Skovgaard
BEBrian Elmengaard
Brian Elmengaard
DCDavid Christiansen
David Christiansen
MHMette Terp Høybye
Mette Terp Høybye
Because of increasing pressure on healthcare resources in many countries, public health policies are increasingly occupied with how to optimise decision‐making processes to ensure medical interventions are appropriate, necessary and aligned with the preferences and values of patients. One prominent example is the concept/model of shared decision‐making (SDM) which target clinician‐patient interactions in the clinic. Such public health goals raise renewed questions about what matters to people when seeking healthcare, which models such as SDM may not be able to fully account for. In this article, we draw on ethnographic fieldwork in two Danish shoulder clinics. We identify specific uncertainties as they manifest in guidelines and the clinic, and draw on pragmatist‐inspired theory, to argue that decision‐making emerges as interactional work in what has been conceptualised as the subjunctive mood, to make treatment proposals acceptable. In this process doubt and hope are inherent elements to be acknowledged and managed, rather than avoided. Thus, we argue that such pragmatist ideals are fundamental to shoulder care. Our findings call for an approach to clinical decision‐making in research and policy that considers the everyday concerns of patients and clinicians as they seek to navigate highly uncertain terrains.